StockNews.com Begins Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

Stock analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ TCON opened at $0.03 on Friday. TRACON Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $14.75. The stock has a market capitalization of $109,802.00, a price-to-earnings ratio of 0.01 and a beta of 1.37. The business has a 50-day moving average of $0.06 and a 200-day moving average of $0.41.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.